STOCK TITAN

Catalent Inc - CTLT STOCK NEWS

Welcome to our dedicated page for Catalent news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent stock.

Overview

Catalent Inc (CTLT) is a global integrated solutions provider specializing in pharmaceutical and biologic development services, innovative drug delivery technologies, and comprehensive manufacturing and packaging solutions. With a heritage of over 80 years, Catalent combines a deep expertise in drug development with a robust commitment to operational excellence. The company acts as a catalyst for success for its partners by streamlining the journey from concept to market, ensuring that molecules are advanced efficiently and effectively.

Core Business Areas

Catalent delivers a wide spectrum of services that address key phases of the pharmaceutical lifecycle. These include:

  • Drug and Biologic Development: Expert formulation development, pre-clinical to clinical manufacturing capabilities, and technology-driven solutions that enhance the bioavailability, solubility, and permeability of drugs.
  • Innovative Drug Delivery Technologies: Cutting-edge solutions designed to optimize the ease and route of administration, addressing critical challenges such as patient compliance and effective dosing.
  • Manufacturing and Packaging Solutions: State-of-the-art controlled manufacturing processes that ensure quality and regulatory compliance, alongside advanced packaging techniques tailored to commercial production requirements.

Market Position and Operational Excellence

Catalent occupies a unique position in the competitive landscape of the pharmaceutical industry. Its strength lies in the breadth and depth of its service offerings, which allow it to support a diverse client base ranging from emerging biotech firms to established pharmaceutical companies. By providing end-to-end solutions, Catalent not only accelerates development timelines but also enhances product performance and market feasibility. This multifaceted approach is instrumental in overcoming common industry challenges, particularly in managing complex supply chains and ensuring consistent product quality.

Global Manufacturing and Supply Chain Capabilities

The company is strategically positioned as a global supplier, capable of addressing manufacturing and commercial packaging needs across different geographies. Catalent’s network of manufacturing and supply facilities is designed to meet the stringent regulatory and quality standards of the sector while providing scalable solutions that can adapt to various target markets. This global footprint underpins its ability to support the distribution and commercialization of pharmaceutical products worldwide.

Research & Development and Technological Innovation

Innovation is central to Catalent's operational philosophy. The company invests significantly in research and development, harnessing advanced technologies to improve drug delivery mechanisms. Its proprietary approaches are tailored to overcome the inherent limitations of traditional pharmaceutical formulations. By integrating science and technology, Catalent enhances product performance, which is critical in an era where efficiency and precision are paramount in therapeutic development. This R&D focus not only streamlines the development process but also drives improvements in therapeutic efficacy and patient compliance.

Integrated Solutions Approach

At its core, Catalent leverages a holistic approach by integrating development, manufacturing, and supply chain solutions. This synergistic model allows the company to serve as a seamless partner throughout the drug lifecycle. The comprehensive service spectrum ensures that each phase, from early-stage development to final product packaging, is managed with a focus on quality, speed, and innovation. The integration of services minimizes the risk of delays and inconsistencies, thereby fostering enhanced drug performance and operational efficiency.

Industry-Specific Expertise

Throughout its operations, Catalent demonstrates a commitment to quality and innovation that is evident in every facet of its business model. By adhering to stringent quality control standards and leveraging technological advancements, the company continues to refine its processes and outcomes. Its methodologies are rooted in decades of industry experience, and its strategic focus on reliable and effective service delivery reinforces its standing as an authoritative source in the pharmaceutical services domain.

In summary, Catalent Inc embodies a synthesis of experience and innovation, offering essential services that underpin critical therapeutic advancements. Its approach is defined by the integration of deep industry knowledge, technological precision, and an unwavering commitment to operational excellence, making it a trusted partner in the complex landscape of drug development and manufacturing.

Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) announced Q1'24 net revenue of $982 million, a 4% decrease from Q1'23. The net loss was $(715) million, including non-cash goodwill impairment charges of $700 million. Adjusted EBITDA was $115 million, a 38% decrease from Q1'23. The company reaffirmed FY'24 financial guidance of $4.3 billion to $4.5 billion in net revenue and $680 million to $760 million in Adjusted EBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.34%
Tags
-
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) will release preliminary financial results for Q1 of fiscal year 2024 on November 15, 2023. A webcast to discuss the results will be hosted at 8:15 a.m. ET on the same day. Interested parties can access the webcast and supplemental slide presentation on Catalent's website. The webcast replay and slides will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.85%
Tags
-
Rhea-AI Summary
ViroCell Biologics appoints Traci Kyes as VP of Business Development (US) and Makis Sigalas as Senior Business Development Director (Europe) to drive growth in respective regions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
Rhea-AI Summary
Catalent, Inc. appoints David McErlane as Group President of Biologics segment, expecting positive impact on business growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
management
-
Rhea-AI Summary
Catalent, Inc. receives notice of non-compliance with NYSE listing requirements due to delayed filing of Annual Report on Form 10-K. Company has six months to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
Rhea-AI Summary
Catalent, Inc. executives to present at investor conferences on September 12 and 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
conferences
Rhea-AI Summary
Catalent announces appointment of four new independent directors and the establishment of a new Strategic and Operational Review Committee. John Greisch appointed as Executive Chair. Enters into Cooperation Agreement with Elliott Investment Management L.P.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
none
-
Rhea-AI Summary
Catalent Inc. reports Q4'23 net revenue of $1.07 billion, a decrease of 17% compared to Q4'22. Q4'23 net loss of $(86) million. Adjusted EBITDA for Q4'23 decreased 61% to $139 million. Fiscal 2023 net revenue decreased 11% to $4.28 billion. FY'24 financial guidance includes net revenue of $4.3 billion to $4.5 billion and Adjusted EBITDA of $680 million to $760 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
-
Rhea-AI Summary
Catalent, Inc. to release Q4 2023 financial results on August 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) appoints Lisa Evoli as Senior Vice President & Chief Human Resources Officer, bringing over 25 years of experience from Integra Lifesciences, TE Connectivity, Johnson & Johnson, and Motorola. She will lead global HR strategy, talent acquisition, leadership development, diversity and inclusion, organizational design, compensation and benefits, HR operations and technology, and performance management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
management

FAQ

What is the current stock price of Catalent (CTLT)?

The current stock price of Catalent (CTLT) is $63.48 as of February 7, 2025.

What is the market cap of Catalent (CTLT)?

The market cap of Catalent (CTLT) is approximately 11.5B.

What is the core business of Catalent Inc?

Catalent Inc focuses on providing integrated solutions for drug and biologic development, innovative delivery technologies, and comprehensive manufacturing and packaging services.

How does Catalent accelerate the development process for pharmaceuticals?

Catalent leverages advanced technologies and a holistic service model that spans early formulation to commercialization, reducing development timelines and enhancing product performance.

What makes Catalent's drug delivery technologies innovative?

The company’s drug delivery solutions improve bioavailability, solubility, and ease of administration, addressing crucial challenges such as dosing efficiency and patient compliance.

How is Catalent positioned in the competitive landscape?

Catalent differentiates itself through its integrated solutions, extensive global manufacturing network, and deep expertise in both drug development and commercial packaging.

What services are included in Catalent's manufacturing capabilities?

Catalent offers scalable manufacturing and packaging solutions that adhere to stringent quality and regulatory standards, ensuring reliable production across diverse markets.

How does Catalent support its global clientele?

With a strategically distributed network of manufacturing and supply facilities, Catalent is equipped to serve diverse global markets while maintaining high-quality standards.

What are the key benefits of Catalent's integrated service approach?

This approach minimizes development risks, streamlines processes from formulation to packaging, and fosters operational efficiency, ultimately enhancing the overall therapeutic value.

How does Catalent maintain quality and innovation in its operations?

Catalent invests in continual research and development and adheres to rigorous quality control protocols, ensuring that its solutions remain reliable and at the forefront of pharmaceutical innovation.
Catalent Inc

NYSE:CTLT

CTLT Rankings

CTLT Stock Data

11.52B
180.20M
0.5%
87.87%
8.12%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SOMERSET